California Stem Cell Agency Symposium: 'Vague Fears' vs. Potential Genetic Alteration of Human Race
By David Jensen,
California Stem Cell Report
| 06. 11. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
California’s $3 billion stem cell agency has called a high-level meeting for next fall to examine a "red-hot" issue that many prominent researchers say could lead ultimately to alteration of the human race.
The topic is a technique that makes it much easier to alter the genetic make-up of individuals in a way that can be inherited by their offspring.
In April, scientists in China reported genetically modifying human embryos in what was regarded as a “world first.” (See
here and
here.)
More recently
Marcy Darnovsky, executive director of the
Center for Genetics and Society in Berkeley,
wrote on May 28 about how the subject was viewed at a meeting called, “Biotech and the Ethical Imagination: A Global Summit.”
“The far end of techno-enthusiastic perspectives, both on human germline modification specifically and on biotech in general, was represented by Harvard experimental psychologist and popular science writer Steven Pinker. In...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
